Tim Knotnerus
Amministratore Delegato presso AgomAb Therapeutics NV
Profilo
Tim Knotnerus is currently the Chief Executive Officer & Director at AgomAb Therapeutics NV since 2019.
Prior to this, he worked as a Senior Associate at Aescap Venture Management BV from 2008 to 2012.
Posizioni attive di Tim Knotnerus
| Società | Posizione | Inizio |
|---|---|---|
AgomAb Therapeutics NV
 AgomAb Therapeutics NV Miscellaneous Commercial ServicesCommercial Services AgomAb Therapeutics NV operates as a Belgian biotherapeutics company, developing agonistic antibodies for regeneration of damaged tissues. The company was founded by Paolo Michieli, Manuela Cazzanti, Virginia Morello, Federica Caterina Linty, Michael Potter Saunders, and Hans J. W. de Haard in 2017 and is headquartered in Ghent, Belgium. | Amministratore Delegato | 01/01/2019 |
Precedenti posizioni note di Tim Knotnerus
| Società | Posizione | Fine |
|---|---|---|
Aescap Venture Management BV
 Aescap Venture Management BV Investment ManagersFinance Aescap Venture Management BV is an independent venture capital investment firm based in Amsterdam. Aescap was founded in 2005 by Michiel de Haan and Dinko Valerio. Inspired by the name of the Greek god of healthcare, Aesculapiu, the firm's name is an acronym for 'Accelerating European Science Companies and Products.' The firm focuses on developing growth in European firms in the biomedical sector. | Analista di Private Equity | 31/05/2012 |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Aziende private | 2 |
|---|---|
Aescap Venture Management BV
Aescap Venture Management BV Investment ManagersFinance Aescap Venture Management BV is an independent venture capital investment firm based in Amsterdam. Aescap was founded in 2005 by Michiel de Haan and Dinko Valerio. Inspired by the name of the Greek god of healthcare, Aesculapiu, the firm's name is an acronym for 'Accelerating European Science Companies and Products.' The firm focuses on developing growth in European firms in the biomedical sector. | Finance |
AgomAb Therapeutics NV
AgomAb Therapeutics NV Miscellaneous Commercial ServicesCommercial Services AgomAb Therapeutics NV operates as a Belgian biotherapeutics company, developing agonistic antibodies for regeneration of damaged tissues. The company was founded by Paolo Michieli, Manuela Cazzanti, Virginia Morello, Federica Caterina Linty, Michael Potter Saunders, and Hans J. W. de Haard in 2017 and is headquartered in Ghent, Belgium. | Commercial Services |
- Borsa valori
- Insiders
- Tim Knotnerus
